Cameron Santoro

Leslie Fish, PharmD, senior vice president of pharmacy at IDP Analytics, LLC, reflects on the future of biosimilars and the impact they will have on managed care pharmacy settings to improve patient access to medications.

Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy, discussed how providers can comfortably switch patients to biosimilars while minimizing anxieties, as well as the impacts prior authorization requirements can have on patient access.

Yuqian Liu, PharmD, Magellan Rx Management, explores the current space of cell and gene therapies based on real-world data and potential emerging therapies in the future, while expanding upon long-term efficacy concerns.

Jenny Craven, PharmD, BCPS, of the University of California Davis Health reviews the finances associated with Emerging Therapy Committee and examines the benefits of the adoption process of new therapies.

Kimberly Westrich, MA, of the National Pharmaceutical Council, addresses the benefits of incorporating patient-centricity throughout the health care system to foster more accurate and better quality of care.

Sarah Bajorek, PharmD, MBA, BCACP, University of California, Davis Health, discusses notable gene therapies emerging into the market and strategies to proactively engage with a wide range of stakeholders during the integration of a new gene therapy.

A survey study found a strong association between severe alopecia areata (AA) and significant impairments in quality of life and mental wellbeing, highlighting the need for comprehensive treatment addressing both physical and emotional aspects of the disease.

Potential links between alopecia areata (AA) and hypothyroidism were observed among the study but the connection between androgenetic alopecia (AG) and hypothyroidism needs further investigation.

Macro-Mediterranean diets for patients with high-risk breast cancer recurrence found no overall reduction, but women who adhered more closely to the diet showed potential benefit.

Young breast cancer survivors without a specific genetic mutation have a lower risk of developing second primary breast cancer within 10 years of diagnosis.

Legal expert in health care, partner, and cochair of the health care coverage and reimbursement practice at Foley Hoag LLP, Ross Margulies discusses his excitement and expectations as a featured speaker at the upcoming 2024 AMCP Annual Conference.

Studies show that laser-assisted drug delivery (LADD) improves hair growth in patients with alopecia. However, researchers are still looking at the best ways to compare LADD's effectiveness against other methods like microneedling.

While mammograms are crucial for early detection of breast cancer and can save lives, social determinants of health and health-related social needs create barriers to access, especially for those with financial hardship, lack of transportation, or social isolation.

Antibodies targeting the CXCL12 protein show potential to promote hair growth in conditions like androgenic alopecia (AGA) and alopecia areata (AA), offering hope for new treatment options.

A recent study found a minor link between prolactin levels and the risk of developing estrogen receptor (ER)-positive or ER-negative breast cancers. However, there was no association found between the use of selective serotonin reuptake inhibitors (SSRIs) and breast cancer risk.

Corticosteroids are the most common treatment for pediatric patients with alopecia areata (AA), but promising newer options like JAK inhibitors are emerging. This review highlights the importance of personalized treatment plans and maximizing response through combination therapies.

Breast cancer survivors face a complex landscape of challenges including lingering symptoms, anxieties about the future, identity shifts, and potential social isolation. However, the study identifies personal growth fostered by the experience, further underscoring the critical role of social support and open communication with health care providers in navigating this journey.

While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires further research for wider adoption.

Red and near-infrared–emitting fabric clothing may improve symptoms of mild psoriasis, polymorphous light eruption (PMLE), and alopecia areata (AA), but further research with larger groups is needed due to limitations in the pilot study design.

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.

Patients with alopecia areata (AA) often perceive their hair loss as more severe than dermatologists do, leading to increased emotional and social problems. This study highlights the importance of understanding patient perception for better treatment and improved quality of life.

Older adults with advanced breast cancer need personalized treatment plans considering fitness, preferences, and potential limitations for optimal outcomes and quality of life.

Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment plans for patients.

Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.

A large-scale study suggests increased light at night exposure is linked to a higher risk of breast cancer, particularly in Asian populations and women with estrogen receptor-positive tumors (ER+).

Baricitinib and other oral JAK inhibitors show promise as effective treatments for moderate-to-severe alopecia areata (AA), with fewer adverse effects compared with traditional options.

Early research suggests ozone therapy may fight breast cancer cells and lessen adverse effects for patients undergoing treatment, but more research is necessary.

A study in San Bernardino County found no increased risks of alopecia areata (AA) after the COVID-19 vaccination but suggests further research into potential geographic and gender-based factors.

A study of patients diagnosed with early breast cancer during the COVID-19 pandemic found that the public health crisis did not produce significant changes in or delays treatment, despite many women presenting with palpable tumors.

A study found baricitinib to be safe and effective for treating severe alopecia areata (AA) but expressed the need for more long-term trials to support these findings.